

Appln No.: 10/605,498  
Amendment Dated: April 20, 2005  
Reply to Office Action of March 23, 2005

**Amendments to the Specification:**

**Please amend the abstract as follows:**

**UBC.P-031 Patent Application**—Therapeutic agents which target heat shock protein (hsp) 27 *in vivo* are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.